Capricor Therapeutics' Overweight Rating Reaffirmed by Piper Sandler

Analysts raise price target on biotech firm's stock to $58 from $45

Mar. 14, 2026 at 10:06am

Got story updates? Submit your updates here. ›

Piper Sandler has reaffirmed its overweight rating on shares of Capricor Therapeutics (NASDAQ:CAPR), a clinical-stage biotechnology company focused on developing cell and exosome-based therapies for cardiovascular and rare diseases. Piper Sandler also raised its price target on Capricor's stock to $58 from the previous $45.

Why it matters

Capricor Therapeutics is a promising biotech firm with a pipeline of innovative therapies targeting conditions like Duchenne muscular dystrophy and COVID-19-related heart injury. The reaffirmation of Piper Sandler's overweight rating and increased price target signals the analysts' continued confidence in the company's prospects and the potential value of its therapeutic candidates.

The details

In its report, Piper Sandler cited Capricor's progress in advancing its lead candidate, CAP-1002, through multiple clinical trials. CAP-1002 comprises allogeneic cardiosphere-derived cells and is being evaluated for the treatment of Duchenne muscular dystrophy and COVID-19-related heart injury. The analysts' increased price target reflects their optimism about Capricor's pipeline and the potential commercial success of its therapies.

  • Piper Sandler issued its report on Friday, March 14, 2026.

The players

Capricor Therapeutics

A clinical-stage biotechnology company focused on developing cell and exosome-based therapies for cardiovascular and rare diseases, headquartered in Beverly Hills, California.

Piper Sandler

An investment bank and financial services firm that has reaffirmed its overweight rating and raised the price target on Capricor Therapeutics' stock.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

Piper Sandler's continued confidence in Capricor Therapeutics and its increased price target suggest the biotech firm's innovative therapies could hold significant commercial potential, underscoring the company's position as a promising player in the development of novel treatments for cardiovascular and rare diseases.